The inhibitory role of specific macrophages in RCC

VISIO PHARM
1/19/21, 11:00 AM
America/Pacific Time UTC -8:00 / -7:00

Description

Only a small subset of patients with clear cell Renal Cell Carcinoma (ccRCC) respond to immunotherapy with checkpoint inhibitors. Research has shown that additional mechanisms of inhibition prevent the majority of patients from successful treatment. Recent studies into the inhibitory role of macrophages portend that these cells are associated with lower survival rate in several different cancer types. In this webinar, Immunologist Prof. Dr. Elfriede Nößner will present her research on specific macrophages in RCC (“ercDCs”) which are associated with poor outcome and their potential as new targets in immune therapy.

 

Learning Objectives

What is known about the role of macrophages in immuno-oncology in general and in RCC specifically

What are “ercDCs” and how do they interact with T-Cells in RCC?

Which possibilities exist to manipulate the ercDCs?

Previous registration necessary?

NO

YES
Simultaneous translation ?

NO

YES
Will it be recorded?
NO
YES

What is known about the role of macrophages in immuno-oncology in general and in RCC specifically, What are “ercDCs” and how do they interact with T-Cells in RCC?, Which possibilities exist to manipulate the ercDCs?

Inglês

 

Speakers

Elfriede Nößner

 

Link to the Event

Banner to the Event

The inhibitory role of specific macrophages in RCC